Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates.
about
Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis.In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazoleEpidemiology of invasive candidiasis: a persistent public health problemDetermination of Echinocandin MICs for Candida species in less than 8 hours: comparison of the rapid susceptibility assay with the Clinical and Laboratory Standards Institute's broth microdilution assay.Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance programCaspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcomeCanadian clinical practice guidelines for invasive candidiasis in adults.Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibilityGlobal surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.Kodamaea ohmeri isolates from patients in a university hospital: identification, antifungal susceptibility, and pulsed-field gel electrophoresis analysis.Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.Role for cell density in antifungal drug resistance in Candida albicans biofilmsRare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.The Ssk1p response regulator and Chk1p histidine kinase mutants of Candida albicans are hypersensitive to fluconazole and voriconazole.Echinocandin antifungals: review and update.Emerging echinocandins for treatment of invasive fungal infections.Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.In vitro and in vivo antifungal activities of T-2307, a novel arylamidine.The echinocandins.Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.Micafungin activity against Candida albicans with diverse azole resistance phenotypes.Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.Molecular phylogenetic analysis of a geographically and temporally matched set of Candida albicans isolates from humans and nonmigratory wildlife in central Illinois.Characterization of caspofungin susceptibilities by broth and agar in Candida albicans clinical isolates with characterized mechanisms of azole resistanceEpidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005.Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes.Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin.In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata.Caspofungin susceptibility testing of Candida inconspicua: correlation of different methods with the minimal fungicidal concentration.Sensititre YeastOne caspofungin susceptibility testing of Candida clinical isolates: correlation with results of NCCLS M27-A2 multicenter study.Assessment of the paradoxical effect of caspofungin in therapy of candidiasisActivities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.Flow cytometry susceptibility testing for the antifungal caspofungin.In vitro susceptibility of Candida isolates from organ transplant recipients to newer antifungals.In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillanceComparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program.Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia.Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.Glucan Synthase Inhibitors
P2860
Q24537282-81E7A8EB-925D-452E-81ED-78EDE451E8C0Q24538858-F787B3EA-78C2-41FE-942B-28BEECC1D16DQ29616758-26E8A1EC-E937-49C1-A219-6B3CC975B95EQ30435993-320A0BD7-6CDF-4127-94F6-ABAB1285EDB3Q30445376-493FAEB9-D6BF-4B93-B962-2981F9103865Q33935389-769EF211-C019-4902-8065-E55A2CDAE4AEQ34237335-A75D7558-A3FB-4EC5-A522-A71D48326D10Q34510707-4F10CD38-8931-4E6A-A630-EAC623F12A1EQ35073614-CB9E7CB4-BEFD-40BE-95F1-FEAA1F9682B6Q35690723-D682C132-3FFD-4B3E-8736-13EB192F4A5DQ35714132-E5FE339C-5A72-4565-A80D-4605A6BFAC91Q35878982-B964E2CB-1722-4324-AB49-A1E1A1E752F2Q35912243-89DC82EC-6C1A-4332-90C0-2E0ECE0FA0B3Q36095050-961F7677-8EAB-426A-8542-84D07ED68A0CQ36441524-5D0EFA36-954D-4ABE-9587-FE3CFB2FD590Q36458402-DB6B0339-459E-4986-99D0-9BC9B69BE0C2Q36497888-9D8B5915-325E-47AB-864D-BD5B18B67246Q36538739-DF26AE12-89B7-4C41-A9A1-99AE8D2E5791Q36742397-F4C4F6FF-731B-41C2-861E-A84B04E7E8F0Q36845482-AAF2C4F7-8FB3-4B8E-A7D3-EDC526416BAFQ36867925-813275B8-A9B2-48C3-8468-9307FCDB7CE9Q36898200-0FC1B655-839D-478C-881E-BB766D672A20Q36899118-480F8685-D765-4FBD-B61F-B1C95231712FQ36925967-4B0FE375-1210-49BE-B03F-02EBE9B89CC6Q37029222-608488FC-0447-4076-8D19-334D7B1F992BQ38586680-2FD7B570-9BDE-43D7-A0A8-AFEEA0EB8B35Q39763435-6BFC2410-CE5A-45DF-9269-1DA39376359FQ41810114-70C374C1-485B-438E-9C35-160384708A64Q41835779-59DAB189-2155-428E-A8FA-38B9A23F9F5CQ41849134-F21DFBD8-7D87-46A4-A401-401C5F9AB8E8Q42051327-9965F4AE-A5AA-42DC-BDDF-4F3B25ADC14DQ42090519-98A2176E-DCC6-4438-9D9B-40CED2D0AED8Q42104395-ADD81FC0-75DF-455F-9967-C047A7397414Q42131206-6E3C9438-7166-494E-BAE4-0816266E9D02Q42221406-DD8E1C12-3605-44B6-8F67-0C6EED5C4F33Q42222929-32A28B4E-0D4D-42C5-9CBA-0208452608EDQ42561331-9C1E6B27-5F1C-49B6-9E9F-00A12D4C37EBQ42846025-59987BC9-C04B-4C08-B8BC-5E217D36D4ADQ42929579-4426A1F4-BF90-4901-A712-3BFFE83C8C17Q58033533-D7D1A3B8-714F-4BF3-909B-AB75A5EC3EFB
P2860
Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Further standardization of bro ...... than 3,000 clinical isolates.
@ast
Further standardization of bro ...... than 3,000 clinical isolates.
@en
type
label
Further standardization of bro ...... than 3,000 clinical isolates.
@ast
Further standardization of bro ...... than 3,000 clinical isolates.
@en
prefLabel
Further standardization of bro ...... than 3,000 clinical isolates.
@ast
Further standardization of bro ...... than 3,000 clinical isolates.
@en
P2093
P2860
P1476
Further standardization of bro ...... e than 3,000 clinical isolates
@en
P2093
P2860
P304
P356
10.1128/JCM.42.7.3117-3119.2004
P407
P577
2004-07-01T00:00:00Z